- Published: 24 April 2024
- Posted: 24 April 2024
Library
- Published: 24 April 2024
- Posted: 24 April 2024
- Published: 05 April 2024
- Posted: 05 April 2024
- Published: 08 May 2023
- Posted: 08 May 2023
- Published: 08 May 2023
- Posted: 08 May 2023
- Published: 24 April 2023
- Posted: 24 April 2023
- Published: 22 December 2024
- Posted: 03 March 2023
- Published: 22 December 2024
- Posted: 02 August 2022
- Published: 22 December 2024
- Posted: 07 March 2023
Dr. Timothy Rebbeck - Harvard University and Dana-Farber Cancer Institute, Boston, United States
Dr. Timothy Rebbeck speaks to ecancer about the strategic training achievements for research success (STARS) programme that aims to increase cancer research capacity in Africa.
He discusses some of the challenges to the advancement of research in Africa and how to overcome those challenges.
The STARS programme is advancing research capacity in Africa by providing a consistent training programme to young investigators on how to write grants, and papers and how to collaborate with other investigators to improve the quality of their research.
Dr. Rebbeck highlights that such practical hands-on training is hard to come by and the STARS programme aims to deliver such training and other resources to improve the quality and the capacity of research in Africa.
- Published: 22 December 2024
- Posted: 16 December 2022
- Published: 22 December 2024
- Posted: 03 August 2022
- Published: 22 December 2024
- Posted: 26 January 2022
While we do cancer clinical trials to test drugs, exposures that increase risks are found with observational studies. These have also been instrumental in highlighting disparities. Tim Rebbeck and Rafa Irizarry discuss the challenges these studies pose. Timothy Rebbeck, PhD is the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard TH Chan School of Public Health and Professor of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Rebbeck’s research focuses on the etiology and prevention of cancer, with an emphasis on cancers with a genetic etiology and those that are associated with disparities in incidence or mortality by race. He has directed multiple large molecular epidemiologic studies and international consortia that have been used to identify and characterize genes involved in cancer etiology, understand the relationship of allelic variation with biochemical or physiological traits, explore interactions of inherited and somatic genomic variation with epidemiological risk factors. Our Data Science Zoominars feature interactive conversation with #datascience experts and a Q+A session moderated by Rafael A. Irizarry, PhD, Chair, Department of Data Science at Dana-Farber Cancer Institute.
- Published: 22 December 2024
- Posted: 08 March 2023
The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to support mentored cancer research career development of early-stage low- and middle-income country (LMIC) investigators (ESLIs). The overarching goal of this supplement opportunity is to strengthen the capacity of LMIC investigators to conduct high-quality research in their LMIC home institutions to generate context-appropriate evidence to address specific cancer control priorities in LMICs.
- Published: 22 December 2024
- Posted: 16 December 2022
- Published: 22 December 2024
- Posted: 20 June 2022
Speaker:
Angelina Fink, Dana-Farber Cancer Institute
Duration: 45 minutes
